NASDAQ:TGTX TG Therapeutics (TGTX) Stock Price, News & Analysis $29.44 +0.67 (+2.33%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$29.48 +0.04 (+0.15%) As of 08/22/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About TG Therapeutics Stock (NASDAQ:TGTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TG Therapeutics alerts:Sign Up Key Stats Today's Range$28.50▼$29.4950-Day Range$26.39▼$39.1952-Week Range$21.11▼$46.48Volume2.18 million shsAverage Volume2.89 million shsMarket Capitalization$4.67 billionP/E Ratio79.57Dividend YieldN/APrice Target$46.25Consensus RatingModerate Buy Company Overview TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. Read More TG Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreTGTX MarketRank™: TG Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 153rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingTG Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTG Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about TG Therapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth1,150.00% Earnings GrowthEarnings for TG Therapeutics are expected to grow by 1,150.00% in the coming year, from $0.08 to $1.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TG Therapeutics is 79.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 28.45.Price to Earnings Ratio vs. SectorThe P/E ratio of TG Therapeutics is 79.57, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.36.Price to Book Value per Share RatioTG Therapeutics has a P/B Ratio of 16.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TG Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.53% of the float of TG Therapeutics has been sold short.Short Interest Ratio / Days to CoverTG Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in TG Therapeutics has recently decreased by 3.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTG Therapeutics does not currently pay a dividend.Dividend GrowthTG Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.5 / 5Environmental Score-1.46 Percentage of Shares Shorted16.53% of the float of TG Therapeutics has been sold short.Short Interest Ratio / Days to CoverTG Therapeutics has a short interest ratio ("days to cover") of 11.4, which indicates bearish sentiment.Change versus previous monthShort interest in TG Therapeutics has recently decreased by 3.02%, indicating that investor sentiment is improving. News and Social Media2.9 / 5News Sentiment1.24 News SentimentTG Therapeutics has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for TG Therapeutics this week, compared to 8 articles on an average week.Search Interest12 people have searched for TGTX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added TG Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, TG Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $369,400.00 in company stock.Percentage Held by Insiders10.64% of the stock of TG Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.58% of the stock of TG Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TG Therapeutics' insider trading history. Receive TGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TG Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TGTX Stock News HeadlinesTG Therapeutics: Looking For The Stimulus For A TurnaroundAugust 20 at 2:09 AM | seekingalpha.comTG Therapeutics' (NASDAQ:TGTX) Anemic Earnings Might Be Worse Than You ThinkAugust 16, 2025 | finance.yahoo.comThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 23 at 2:00 AM | Paradigm Press (Ad)TG Therapeutics files automatic mixed securities shelfAugust 9, 2025 | msn.comBeyond the Balance Sheet: What SWOT Reveals About TG Therapeutics Inc (TGTX)August 8, 2025 | gurufocus.comWhy Top 3% Stock TG Therapeutics Crashed Despite Raising Its 2025 OutlookAugust 6, 2025 | msn.comTG Therapeutics Stock Tumbles 16% After Disappointing Q2, But Company Reaffirms Confidence In Multiple Sclerosis DrugAugust 6, 2025 | msn.comTG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales GuidanceAugust 5, 2025 | insidermonkey.comSee More Headlines TGTX Stock Analysis - Frequently Asked Questions How have TGTX shares performed this year? TG Therapeutics' stock was trading at $30.10 at the beginning of the year. Since then, TGTX stock has decreased by 2.2% and is now trading at $29.44. How were TG Therapeutics' earnings last quarter? TG Therapeutics, Inc. (NASDAQ:TGTX) posted its quarterly earnings data on Monday, August, 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by $0.15. TG Therapeutics's revenue was up 92.1% compared to the same quarter last year. Read the conference call transcript. Who are TG Therapeutics' major shareholders? TG Therapeutics' top institutional shareholders include State Street Corp (4.80%), Geode Capital Management LLC (2.20%), Soleus Capital Management L.P. (1.41%) and Hood River Capital Management LLC (0.99%). Insiders that own company stock include Michael S Weiss, Sean A Power, Yann Echelard, Laurence N Charney and Sagar Lonial. View institutional ownership trends. How do I buy shares of TG Therapeutics? Shares of TGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of TG Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that TG Therapeutics investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings8/04/2025Today8/23/2025Next Earnings (Estimated)11/03/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TGTX CIK1001316 Webwww.tgtherapeutics.com Phone(212) 554-4484Fax212-554-4531Employees290Year FoundedN/APrice Target and Rating Average Price Target for TG Therapeutics$46.25 High Price Target$55.00 Low Price Target$37.00 Potential Upside/Downside+57.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)$0.37 Trailing P/E Ratio79.57 Forward P/E Ratio368.00 P/E GrowthN/ANet Income$23.38 million Net Margins13.31% Pretax Margin14.56% Return on Equity26.05% Return on Assets9.58% Debt Debt-to-Equity Ratio0.89 Current Ratio3.86 Quick Ratio2.96 Sales & Book Value Annual Sales$329 million Price / Sales14.20 Cash Flow$0.12 per share Price / Cash Flow239.82 Book Value$1.74 per share Price / Book16.92Miscellaneous Outstanding Shares158,670,000Free Float141,784,000Market Cap$4.67 billion OptionableOptionable Beta1.95 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:TGTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TG Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TG Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.